Screener
Eligibility screening
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
1 US site in CA
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.
Screener
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
1 US site in CA
Before we begin
Your answer affects how the questions are phrased.